Relevant bibliographies by topics / Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'Precursor T-Cell Lymphoblastic Leukemia-Lymphoma'

Author: Grafiati
Published: 4 June 2021
Last updated: 6 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Precursor T-Cell Lymphoblastic Leukemia-Lymphoma.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Precursor T-Cell Lymphoblastic Leukemia-Lymphoma"

1

Lazarchick, J. "Precursor T-Lymphoblastic Leukemia/Lymphoma." ASH Image Bank 2001, no. 1205 (December 5, 2001): 100187. http://dx.doi.org/10.1182/ashimagebank-2001-100187.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Czuchlewski, David R., and Kathryn Foucar. "Early T-cell Precursor Acute Lymphoblastic Leukemia/Lymphoma." Surgical Pathology Clinics 6, no. 4 (December 2013): 661–76. http://dx.doi.org/10.1016/j.path.2013.08.002.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Chang, Myung Hee, Seok Jin Kim, Won Seog Kim, Chul Won Choi, Cheolwon Suh, Sung Hyun Kim, Deok-Hwan Yang, Jong-Ho Won, and Soon Il Lee. "Treatment Outcome and Prognostic Factors in Patients with Precursor B and T Lymphoblastic Lymphoma." Blood 112, no. 11 (November 16, 2008): 3601. http://dx.doi.org/10.1182/blood.v112.11.3601.3601.

Full text
Abstract:
Abstract Introduction: Lymphoblastic lymphoma is an uncommom subtype of non-Hodgkin’s lymphoma. Lymphoblastic lymphoma represents a distinctive lymphoma entity with cytological and histological features similar to those of acut lymphoblastic leukemia (ALL). Thus, World Health Organization (WHO) classification classifies this disease entity as precursor B and T lymphoblastic lymphoma/leukemia. At present, precursor B and T lymphoblastic lymphoma has been treated with intensive chemotherapy similar to acute lymphoblastic leukemia. However, there is few study about the treatment outcome and prognostic factors in precursor B and T lymphoblastic lymphoma presenting as lymphoma not leukemia. Thus. the purpose of this retrospective study was to investigate clinical features and treatment outcomes of lymphoblastic lymphoma. Patients and methods: We analyzed 62 patients newly diagnosed with precursor B and T lymhpoblastic lymphoma. All patients were histologically confirmed by pathologists between October 1996 and November 2007, who met the following criteria were included in this retrospective evaluation: age over 15 years, presence of an extramedullary primary and ≤20% blasts in bone marrow, the presence of lymphoblastic histology, the immunophenotype of the malignant cells. Results: The patients were male predominent (77%), with 77% (48) of patients having a T-cell immunophenotype. The median age at time of presentation was 28.5 years (16–69). The presenting sites of primary disease included mediastinal mass in twenty-eight cases. The bone marrow was involved in 22.6% (14) patients. Extranodal involvements were found in 40 patients. Four major chemotherapeutic regimens including vincristine, prednisone, daunorubicin, L-asparginase (VPDL), CALGB 19802, Standford/NCOG, CHOP were used to treat 25,12,9 and 5 patients, respectively. Eleven other patients were treated with five different chemotherapeutic regimens, respectively. Two patients in relapse received allogeneic stem cell transplantation, and the other two received autologous stem cell transplantation. In 19 patients with first complete response, they were treated with autologous stem cell transplantation. When we compared precursor T lymphoblastic lymphoma with precursor B lymphoblastic lymphoma, precursor T lymphoblastic lymphoma showed older age (40≤ p=0.031), more mediastinal involvement (p=0.002), and male predominenance (p=0.005). Overall response rate of patients treated with initial chemotherapy was 83.9% (50% of CR, 33.9% of PR). Event-free survival (EFS) and overall survival (OS) rate at 30 months were estimated to be 53%±6 and 59%±6, respectively, with a median follow-up of 31 months. Twenty-six of 52 relapses occurred. ALL-type chemotherapy is not superior to conventional chemotherapy used for non-Hodgkin’s lymphoma (p=0.531). The survival differences was observed between stage I to III patients and IV patients (p=0.007), and patients with and without two or more extranodal sites of disease(p=0.038). There is no difference between precursor B lymphoblastic lymphoma and precursor B lymphoblastic lymphoma. Therefore, stage IV and two or more than two of extranodal involvements were found to be as prognostic factor in precursor B and T lymphoblastic lymphoma. Conclusion: Overall prognosis of precursor B and T lymphoblastic lymphoma was poor although they showed a good response to chemotherapy because of their high relpase rate. And stage and the number of extranodal involvement are two pretreatment prognostic factors for adult lymphoblastic lymphoma. Thus, newer treatment strategy adapted on the poor prognostic factors should be warranted.
APA, Harvard, Vancouver, ISO, and other styles
4

Han, Xin, and Carlos E. Bueso-Ramos. "Precursor T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma and Acute Biphenotypic Leukemias." American Journal of Clinical Pathology 127, no. 4 (April 2007): 528–44. http://dx.doi.org/10.1309/2qe3a6ekq8uydyrc.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Hirzel, Alicia C., Aaron Cotrell, Robert Gasparini, and Vathany Sriganeshan. "Precursor B-Cell Acute Lymphoblastic Leukemia/Lymphoma with L3 Morphology, Philadelphia Chromosome, MYC Gene Translocation, and Coexpression of TdT and Surface Light Chains: A Case Report." Case Reports in Pathology 2013 (2013): 1–4. http://dx.doi.org/10.1155/2013/679892.

Full text
Abstract:
Acute lymphoblastic leukemia is predominantly found in children. It is a neoplasm of precursor cells or lymphoblasts committed to either a B- or T-cell lineage. The immature cells in B-acute lymphoblastic leukemia/lymphoma can be small or medium sized with scant or moderate cytoplasm and typically express B-cell markers such as CD19, cytoplasmic CD79a, and TdT without surface light chains. These markers, along with cytogenetic studies, are vital to the diagnosis, classification, and treatment of these neoplasms. We present an unusual case of a precursor B-cell ALL, in an 82-year-old woman, who presented with pancytopenia and widespread lymphadenopathy. The cells show L3 morphology (Burkitt-like lymphoma) with coexpression of TdT and surface light chains in addition to an MYC gene translocation and Philadelphia chromosome.
APA, Harvard, Vancouver, ISO, and other styles
6

Maslak, P. "Precursor T-cell Acute Lymphoblastic Leukemia." ASH Image Bank 2003, no. 1231 (December 31, 2003): 100945. http://dx.doi.org/10.1182/ashimagebank-2003-100945.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Pervez, Hira, Salwa Pervez, Soomro Niaz, and Saima Imam. "Huge complex mediastinal mass presenting as a rare variant of lymphoblastic leukemia/lymphoma." Professional Medical Journal 27, no. 10 (October 10, 2020): 2271–78. http://dx.doi.org/10.29309/tpmj/2020.27.10.4156.

Full text
Abstract:
The mediastinum is the space that separates the lungs from the rest of the chest. The most common mediastinal masses are neurogenic tumors (20% of mediastinal tumors), followed by thymoma (15-20%). Other masses include lymphoma, pheochromocytoma, germ cell tumors, including teratoma, thyroid tissue, and parathyroid lesions. Lymphoblastic leukemias/lymphomas are neoplasms of precursor T cells and B cells also known lymphoblasts. World Health Organization (WHO) classification has unified these entities as precursor B-cell and T-cell lymphoblastic leukemia/lymphoma. We present here a rare variant of non-Hodgkins lymphoma in a 12-year-old female who complained of worsening dyspnea and lower left-sided chest pain. The patient was empirically treated with anti-tuberculous drugs without relief. On admission, a CT scan chest showed an anterior mediastinal mass approximately 25x12.5 cm adherent to the mediastinal structures. Resection of the mass was done sparing the phrenic nerve. The sample was sent for histopathology which suggested small cells with hyperchromatic nuclei and positive tumor markers. Rare occurrence of this ailment can lead to mistakes with the diagnosis. Therefore the uniqueness of our case lies in the fact that a T-LBL can present with such a huge mass.
APA, Harvard, Vancouver, ISO, and other styles
8

Viardot, Andreas, Franco Locatelli, Julia Stieglmaier, Faraz Zaman, and Elias Jabbour. "Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies." Annals of Hematology 99, no. 10 (August 27, 2020): 2215–29. http://dx.doi.org/10.1007/s00277-020-04221-0.

Full text
Abstract:
Abstract The B cell surface antigen CD19 is a target for treating B cell malignancies, such as B cell precursor acute lymphoblastic leukemia and B cell non-Hodgkin lymphoma. The BiTE® immuno-oncology platform includes blinatumomab, which is approved for relapsed/refractory B cell precursor acute lymphoblastic leukemia and B cell precursor acute lymphoblastic leukemia with minimal residual disease. Blinatumomab is also being evaluated in combination with other agents (tyrosine kinase inhibitors, checkpoint inhibitors, and chemotherapy) in various treatment settings, including frontline protocols. An extended half-life BiTE molecule is also under investigation. Patients receiving blinatumomab may experience cytokine release syndrome and neurotoxicity; however, these events may be less frequent and severe than in patients receiving other CD19-targeted immunotherapies, such as chimeric antigen receptor T cell therapy. We review BiTE technology for treating malignancies that express CD19, analyzing the benefits and limitations of this bispecific T cell engager platform from clinical experience with blinatumomab.
APA, Harvard, Vancouver, ISO, and other styles
9

Wang, Ping, Xian’gui Peng, Xiaojuan Deng, Li Gao, Xi Zhang, and Yimei Feng. "Diagnostic challenges in T-lymphoblastic lymphoma, early T-cell precursor acute lymphoblastic leukemia or mixed phenotype acute leukemia." Medicine 97, no. 41 (October 2018): e12743. http://dx.doi.org/10.1097/md.0000000000012743.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Li, Shiyong, and Glen Lew. "Is B-Lineage Acute Lymphoblastic Leukemia With a Mature Phenotype and L1 Morphology a Precursor B-Lymphoblastic Leukemia/Lymphoma or Burkitt Leukemia/Lymphoma?" Archives of Pathology & Laboratory Medicine 127, no. 10 (October 1, 2003): 1340–44. http://dx.doi.org/10.5858/2003-127-1340-iballw.

Full text
Abstract:
Abstract Context.—B-lineage acute lymphoblastic leukemia (ALL) with a mature phenotype and L1 morphology is a rare condition that may pose a diagnostic and management challenge. Objective.—To report our experience with 2 such unusual cases of pediatric B-lineage ALL. Design.—Morphologic, immunophenotypic, and cytogenetic features of the leukemic blast cells were reviewed in conjunction with clinical and other laboratory findings. Results.—The leukemic blast cells in both cases were small to medium with scant basophilic cytoplasm and several small inconspicuous nucleoli, characteristic of L1 lymphoblasts. Immunophenotypically, they were positive for CD19, CD22, and low-density CD20, with expression of surface immunoglobulin λ light chain. They were negative for immature (CD34 and terminal deoxynucleotidyl transferase), myeloid, and T-cell–associated markers. Conventional cytogenetic and fluorescent in situ hybridization studies failed to demonstrate chromosomal translocations involving the c-myc gene. Both patients were treated with Children's Cancer Group ALL protocols and had good responses. Conclusions.—B-lineage ALL with a mature phenotype, L1 morphology, and absent chromosomal translocations involving the c-myc gene is best classified and managed as precursor B-lymphoblastic leukemia/lymphoma instead of Burkitt leukemia/lymphoma.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Precursor T-Cell Lymphoblastic Leukemia-Lymphoma"

1

Tesell, Jessica M. "The Notch1-c-Myc Pathway Mediates Leukemia-Initiating Cell Activity in Mouse T-ALL Models: A Dissertation." eScholarship@UMMS, 2013. http://escholarship.umassmed.edu/gsbs_diss/671.

Full text
Abstract:
Although cure rates have significantly improved for children with T-cell acute lymphoblastic leukemia (T-ALL), 20-30% undergo induction failure or relapse with most succumbing to disease. Leukemia-initiating cells (L-ICs) are hypothesized to be resistant to conventional chemotherapy and radiation and are thereby responsible for disease recurrence. Using an in vivo limiting dilution assay, we previously showed that the murine T-ALL L-IC is quite rare, with only 0.003-0.05% of cells capable of initiating disease, and demonstrated that the L-IC is a subset of the leukemic DN3 thymic progenitor population. Work described in this thesis validates the L-IC assay using two transplantation methods to rule out effects of homing and/or microenvironment on T-ALL L-IC survival and maintenance. Using this assay, we demonstrate that sustained Notch1 signaling is required for T-ALL initiation in vivo and show that treatment with a Notch1 inhibitor reduces or in some cases eliminates the L-IC population. We further analyze the effects of inhibiting c-Myc, a Notch1-regulated gene, on L-IC frequency and uncover an essential role for c-Myc in L-IC survival and expansion. Suppressing c-Myc by using specific shRNAs or a c-Myc inhibitor reduces the L-IC population and interferes with leukemia initiation. Together, these findings reveal a critical role of the Notch1-c-Myc pathway in T-ALL initiation and suggest that therapeutics targeted at this pathway could be used to treat and/or prevent disease relapse in patients.
APA, Harvard, Vancouver, ISO, and other styles
2

Thörn, Ingrid. "Minimal Residual Disease Assessment in Childhood Acute Lymphoblastic Leukemia." Uppsala : Acta Universitatis Upsaliensis : Univ.-bibl. [distributör], 2009. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-101028.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Akers, Stephen Matthew. "Modeling central nervous system involvement in acute lymphoblastic leukemia." Morgantown, W. Va. : [West Virginia University Libraries], 2010. http://hdl.handle.net/10450/11227.

Full text
Abstract:
Thesis (Ph. D.)--West Virginia University, 2010.
Title from document title page. Document formatted into pages; contains x, 102 p. : ill. (some col.). Includes abstract. Includes bibliographical references.
APA, Harvard, Vancouver, ISO, and other styles
4

Tidwell, Jerithea Doronice d. 1972. "Sleep, fatigue and caregiver burden in parents of children with acute lymphoblastic leukemia (ALL)." View the abstract Download the full-text PDF version (on campus access only), 2008. http://etd.utmem.edu/ABSTRACTS/2008-004-Tidwell-Index.html.

Full text
Abstract:
Thesis (Ph.D.)--University of Tennessee Health Science Center, 2008
Title from title page screen (viewed on June 19, 2008). Research advisor: Pamela S. Hinds RN, Ph.D. Document formatted into pages (viii, 185 p. : ill.). Vita. Abstract. Includes bibliographical references (p. 86-98).
APA, Harvard, Vancouver, ISO, and other styles
5

Jotta, Patricia Yoshioka 1985. "Mutações de PTEN nas leucemias linfóides agudas T." [s.n.], 2012. http://repositorio.unicamp.br/jspui/handle/REPOSIP/316892.

Full text
Abstract:
Orientador: José Andres Yunes
Tese (doutorado) - Universidade Estadual de Campinas, Instituto de Biologia
Made available in DSpace on 2018-08-21T05:50:44Z (GMT). No. of bitstreams: 1 Jotta_PatriciaYoshioka_D.pdf: 8922035 bytes, checksum: 3734371a320410ba431d6e6ce6579e55 (MD5) Previous issue date: 2012
Resumo: A leucemia linfóide aguda (LLA) é o câncer mais frequente na infância, e destas, 15% são do tipo T (LLA-T). A hiperativação da via PI3K/Akt tem sido amplamente descrita em tumores e em linhagens celulares de LLA-T. PTEN é o principal regulador negativo dessa via e frequentemente encontra-se inativado em cânceres humanos. Com frequência, pacientes com LLA-T apresentam mutações ativadoras de NOTCH1. NOTCH1 pode regular transcricionalmente PTEN, contudo ainda não está claro como as mutações ativadoras de NOTCH1 influenciariam a expressão de PTEN nas LLA-T. Nós encontramos uma ocorrência de 11 (17,7%) mutações no éxon 7 do PTEN em 62 casos de LLA-T estudados consecutivamente. Contudo, nenhuma mutação foi encontrada na análise de 71 casos de LLA-B derivada. A maioria das mutações de PTEN apresentavam inserções/deleções de mais de 3 nucleotídeos. Não encontramos associação entre mutações em PTEN e o gênero, a idade e a contagem de glóbulos brancos ao diagnóstico. Pacientes com alterações no PTEN apresentaram uma tendência a pior sobrevida global (OS, p=0.07). Dentre os pacientes de LLA-T classificados como alto risco (n=56), aqueles possuindo anormalidades no PTEN mostraram-se associados significativamente a menor OS (p=0.019) e sobrevida livre de leucemia (LFS 47% vs 76%; p=0.045). As curvas de LFS foram significativamente diferentes (p=0.003), mesmo considerando apenas pacientes que atingiram a remissão no dia 28 do tratamento para a análise. Nosso estudo também mostrou que pacientes com mutações em NOTCH1 apresentavam aumento na transcrição de MYC e menor expressão de PTEN mRNA comparados a pacientes com NOTCH1 selvagem. Nós recentemente demonstramos que células de LLA-T apresentavam fosforilação de PTEN mediada por CK2, resultando na estabilização e consequentemente inativação da proteína PTEN. Corroborando ao estudo anterior, os casos de LLA-T analisados, independente do status de mutação em NOTCH1, expressam níveis significativamente mais altos de proteína PTEN do que controles normais. Para avaliar o impacto da regulação transcricional de NOTCH e a inativação postranscricional por CK2 de PTEN, nós tratamos as células de LLA-T com inibidores de gamma-secretase (DAPT e de CK2 (DRB/TBB). Nosso estudo enfatiza a relevância biológica e clínica da regulação do PTEN em LLA-T. E sugerimos o uso combinado de inibidores de gamma-secretase e CK2 devem possuir potencial terapêutico nas LLA-T
Abstract: T-cell acute lymphoblastic leukemia (T-ALL) accounts for approximately 15% of pediatric ALL. Patients with T-ALL are at increased risk of relapse compared with children treated for B-cell precursor ALL. Mutations in the phosphatase and tensin homolog (PTEN) gene leading to PTEN protein deletion and subsequent activation of the PI3K/Akt signaling pathway are common in cancer. PTEN is the main negative regulator of the PI3K/Akt survival pathway. T-ALL patients frequently display NOTCH1 activating mutations and Notch can transcriptionally down-regulate the tumor suppressor PTEN. However, it is not clear whether NOTCH1 mutations associate with decreased PTEN expression in primary T-ALL. We report that PTEN exon 7 mutations occurred in 11 (17.7%) out of 62 consecutive pediatric T-cell acute lymphoblastic leukemia (T-ALL) but in none of 71 precursor B-ALL patients. Most PTEN mutations were insertions/deletions of more than 3 nucleotides. No associations were found between PTEN mutation and age, gender, WBC at diagnosis, early response to therapy and remission rate. Patients with PTEN mutation (n=11) had a tendency toward worse overall survival (OS, p=0.07). Remarkably, PTEN mutations were significantly associated with lower OS (p=0.019) and leukemia-free survival (LFS 47% vs 76%, p=0.045) within patients classified in the high risk group (n=56). LFS curves were significantly different (p=0.003) even if only patients who reached remission on day 28 were considered for analysis. We compared patients with or without NOTCH1mutations and report that the former presented higher MYC transcript levels and decreased PTEN mRNA expression. We recently showed that T-ALL cells frequently display CK2-mediated PTEN phosphorylation, resulting in PTEN protein stabilization and concomitant functional inactivation. Accordingly, the T-ALL samples analyzed, irrespectively of their NOTCH1 mutational status, expressed significantly higher PTEN protein levels than normal controls. To evaluate the integrated functional impact of NOTCH transcriptional and CK2 post-translational inactivation of PTEN, we treated TALL cells with both the gamma-secretase inhibitor DAPT and the CK2 inhibitors DRB/TBB. Our data suggest that combined use of gamma-secretase and CK2 inhibitors may have therapeutic potential in T-ALL. And emphasize the biological and clinical relevance of PTEN regulation in pediatric T-ALL
Doutorado
Genetica Animal e Evolução
Doutor em Genetica e Biologia Molecular
APA, Harvard, Vancouver, ISO, and other styles
6

Gallo, Llorente Lucía [Verfasser], and Reinhard [Akademischer Betreuer] Schneppenheim. "Analysis of NOTCH1 Mutation Status in Precursor T-Cell Lymphoblastic Leukemia of Childhood: Prognostic Value and Correlation with Early Treatment Response / Lucía Gallo Llorente. Betreuer: Reinhard Schneppenheim." Hamburg : Staats- und Universitätsbibliothek Hamburg, 2012. http://d-nb.info/1024772667/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Cullion, Kathleen J. "Mechanisms of NOTCH1 Mediated Leukemogenesis: A Dissertation." eScholarship@UMMS, 2009. https://escholarship.umassmed.edu/gsbs_diss/537.

Full text
Abstract:
Gain of function NOTCH1 mutations are common in both patients with T-ALL and in mouse models of the disease. Inhibiting the Notch pathway in T-ALL cell lines results in growth arrest and/or apoptosis in vitro, suggesting a requirement for Notch signaling in T-ALL. Therefore, we sought to examine the role of Notch1 signaling in both premalignancy and in the maintenance of leukemic growth. Using a murine model of T-ALL, in which expression of the Tal1 and Lmo2 oncogenes arrests thymocyte development, our preleukemic studies reveal that Notch1 mutations are early events that contribute to the clonal expansion of DN3 and DN4 progenitors. We also demonstrate that progenitors are maintained within the tumor and are enriched in leukemia-initiating cell (L-IC) activity, suggesting Notch1 may contribute to L-IC self-renewal. By studying the effects of Notch signaling in murine T-ALL cell lines, we also demonstrate that Notch1 promotes the proliferation and survival of leukemic blasts through regulation of Lef1 and the Akt/mTOR pathways. Given that T-ALL cell lines are dependent on Notch signaling in vitro, we investigated the effects of Notch inhibition in vivo. We provide evidence that Notch1 can be successfully targeted in vivo and that Notch inhibition, with γ-secretase inhibitors (GSIs), significantly extends the survival of leukemic mice. We also demonstrate that administration of GSIs in combination with rapamycin inhibits human T-ALL growth and extends survival in a mouse xenograft model. Given that NOTCH1 may be required to maintain both L-IC and bulk leukemic growth, targeting NOTCH1 may prove to be an efficacious targeted therapy for T-ALL patients with aberrant NOTCH1 activation.
APA, Harvard, Vancouver, ISO, and other styles
8

Pereira, Waldir Veiga. "Aspectos epidemiológicos, biotipologia e evolução do tratamento da leucemia linfocítica aguda na infância e adolescência no Rio Grande do Sul." Universidade de São Paulo, 2010. http://www.teses.usp.br/teses/disponiveis/5/5141/tde-22092010-144728/.

Full text
Abstract:
A Leucemia Linfocítica Aguda na infância e adolescência é uma neoplasia de precursores linfóides de natureza heterogênea. Foi a primeira neoplasia disseminada a tornar-se curável pela quimioterapia. No Brasil os estudos cooperativos para o seu tratamento foram iniciados em 1980 com a criação do primeiro protocolo para o tratamento desta leucemia, denominado Grupo Brasileiro para o Tratamento da Leucemia na Infância. Na seqüência destes estudos foram observadas Sobrevidas Livre de Eventos de 50%, 58% e 70% nos protocolos 80, 82 e 85 respectivamente. Durante as décadas de 1980 e 1990, com a divulgação dos excelentes resultados alcançados com os regimes dos protocolos do grupo Berlin Frankfurt Münster, uma série de instituições em nosso País passou a adotá-los. Apesar de termos conhecimento dos dados referentes a evolução dos pacientes protocolados no GBTLI e dos demais estudos divulgados pelas instituições de origem, não tínhamos, porém, uma avaliação epidemiológica nem o conhecimento dos índices de sobrevivência alcançados no estado do Rio Grande do Sul. Neste trabalho foram avaliados 1472 pacientes com LLA, 833 (56,59%) do sexo masculino, 639 (43,41%) do sexo feminino, com idades entre zero e 20 anos, média de 7,40 anos (desvio padrão 5,14) e mediana de 5,70 anos (amplitude 0,06 a 20,76), no período de 1980 a 2008 provenientes deste Estado. Os dados foram colhidos individualmente dos prontuários dos pacientes admitidos nas principais instituições hospitalares que mantém assistência a pacientes pediátricos com neoplasias hematológicas. No presente estudo 487 pacientes (39,40%) foram registrados oficialmente nos protocolos do GBTLI; 678 (54,85%) receberam tratamento baseados nos regimes do grupo BFM e 71 (5,75%) por outros regimes incluindo os tratados segundo o protocolo UKALL. Os casos não foram, no entanto, protocolados e, na grande maioria não foram observados a totalidade dos itens exigidos para os pacientes registrados oficialmente. A sobrevida livre de eventos dos pacientes protocolados foi significativamente superior comparada aos não protocolados, 62,41% ± 2,43% e 53,86% ± 2,04% respectivamente, em cinco anos. De acordo com a faixa etária os pacientes que apresentavam idade de 15 a 19 anos tiveram um índice de SLE de 37,98% ± 4,72% em cinco anos, inferior quando comparado aos de zero a 4 anos e 5 a 9 anos respectivamente: 62,78% ± 2,28% e 62,43% ± 2,84%. Foi observada, na população estudada, uma SG de 63,73% ± 1,49% e SLE de 57,27% ± 1,57%, o que sugere uma discussão para implementar projetos com a finalidade de elevar estes índices de sobrevida. Epidemiologicamente a incidência da LLA com progenitores B seguiu o padrão observado em países desenvolvidos com um pico de freqüência absoluta entre as idades de 2 a 4 anos. Houve diferença significativa entre a população proveniente da região urbana ou rural sendo a SLE em cinco anos de 61,76% ± 1,76% e 49,81% ± 4,28% respectivamente. A SLE e a SG em lactentes e portadores de Síndrome de Down foi inferior aos resultados obtidos em instituições dos países desenvolvidos o que torna aconselhável uma revisão das condições para a assistência destes pacientes. Este estudo teve como finalidade principal retratar a situação passada e a atual do tratamento da LLA na infância e adolescência no Rio Grande do Sul e acumular dados aqui não interpretados e que poderão ser analisados posteriormente
Acute lymphocytic leukemia in childhood and adolescence is a neoplastic disease of lymphoid precursor of heterogeneous nature, being the first disseminated neoplasia to become curable through Chemotherapy. In Brazil, cooperative studies for the treatment of ALL started in 1980 with the creation of the first protocol by the Grupo Brasileiro para o Tratamento da Leucemia na Infância. According to these studies, Event Free Survival of 50%, 58% and 70% in the protocols of 1980, 1982 e 1985 respectively was observed. During the 80s and 90s many Brazilian institutions adopted the protocols motivated by the excellent results achieved by the Berlin Frankfurt Münster group. In spite of the knowledge provided by data related to the evolution of patients protocoled by the GBTLI and other studies published by medical institutions, there was not an epidemiologic evaluation or knowledge of survival indexes achieved in the state of Rio Grande do Sul. In this work, 1472 patients with ALL from the state of Rio Grande do Sul were evaluated. Among the subjects, 833 (56,59%) were male, 639 (43,41%) female, with age range between 0- 20 y average age of 7,40 (standard deviation 5,14) and median 5,70 years old (amplitude 0,06 to 20,76). Data was collected from the medical registers of patients with hematologic neoplasia in medical institutions, which offered pediatric assistance for ALL comprising the period between 1980 until 2008. In the present study, 487 patients (39,40%) were officially registered in the protocols of GBTLI; 678 (54,85%) received treatment based on the regime of the BFM group and 71 (5,75%) were treated according to other regimens (including the UKALL protocol). The cases, however, were not protocoled and, in most cases, the totality of items required for the patients registered officially were not observed. The EFS of the patients protocoled were significantly superior to those who were not protocoled (62,41% ± 2,43% and 53,86% ± 2,04% respectively) in five years. In respect to the age range, the patients which were between 15-20 years had an EFS index of 37,98% ± 4,72% in five years, which is inferior to the index of patients 0-4 years and 5-9 years: 62,78% ± 2,28% e 62,543± 2,84% respectively. An overall survival (OS) of 63,73% ± 1,49% and EFS of 57,27% ± 1,57% was observed in the population studied. These results indicate that a discussion for the implementation of projects, which can increase the indexes of cure, should be carried out. Epidemiologically, the incidence of ALL in B progenitors followed the pattern observed in developed countries with an absolute frequency peak in the age range of 2-4 years. The outcome was superior for patients coming from urban area in comparison to those from rural area. EFS and OS in infant and Down syndrome patients were inferior to the results obtained in developed countries, showing how important it is to review the conditions of the assistance provided to these patients. The objective of this work is to present the development of ALL treatment in childhood and adolescence in the state of Rio Grande do Sul, Brazil, from its beginning until the current days providing data, which can be analyzed and interpreted posteriorly
APA, Harvard, Vancouver, ISO, and other styles
9

Souza, Clelia Marta Casellato de. "Avaliação da qualidade de vida de sobreviventes de câncer na infância: uma proposta alternativa de coleta de dados." Universidade de São Paulo, 2014. http://www.teses.usp.br/teses/disponiveis/5/5141/tde-13012015-110853/.

Full text
Abstract:
O acometimento do câncer na infância é relativamente raro, com taxas relevantes de incidência de alguns tumores, como a leucemia linfoblástica aguda (LLA) e o tumor de Wilms (TW). Embora o câncer seja uma das dez primeiras causas de óbito de crianças e adolescentes e a primeira por doença a partir dos cinco anos, nas últimas décadas o progresso da terapêutica tem possibilitado um declínio nas taxas de mortalidade e expansão dos prazos de sobrevida. Desta forma, o acompanhamento efetivo no enfrentamento da doença passou a buscar análises mais amplas dos efeitos orgânicos tardios da doença e da terapêutica, incluindo as condições psicossociais do sobrevivente, como nas avaliações da qualidade de vida relacionada à saúde (QVRS). No sentido de ampliar o conhecimento e alternativas para o acompanhamento ambulatorial e periódico da condição de sobrevivência, este estudo buscou comparar o impacto na QVRS do sobrevivente adulto, dada a diferença na terapêutica de escolha para a remissão da LLA (quimioterapia) e do TW (cirurgia e quimioterapia), utilizando uma avaliação a distância da QVRS (SF-36, via telefone).Objetivos: Analisar e comparar a QVRS de sobreviventes adultos de LLA e TW, entre si e em relação a participantes sadios, acompanhados no Ambulatório Fora de Terapia do ITACI-HC-FMUSP, através da aplicação alternativa (via telefone) do SF-36.Casuística e Método: 90 participantes, acima de 18 anos. Grupo controle(CTRL) (30 sujeitos, fisicamente saudáveis, com ausência de diagnóstico prévio de câncer, recém-ingressos em curso superior) e Grupos experimentais (60 sobreviventes - Ambulatório Fora de Terapia - ITACI - HCFMUSP): grupo LLA (GLLA) - 30 sobreviventes LLA e grupo TW (GTW) 30 sobreviventes TW. A avaliação foi realizada através da aplicação, via telefone, do SF- 36. Após compilação dos domínios do SF-36, os resultados foram analisados através do teste de qui-quadrado, teste t-independente e teste de ANOVA. Resultados: Os participantes não apresentaram diferença significativa quanto a idade, a maioria eram solteiros, sem filhos e provenientes de São Paulo. O nível mais elevado de escolaridade do CTRL decorreu do critério de inclusão, mas com relevante proporção de sobreviventes no nível superior. Nos sobreviventes não houve diferença significativa de idade de diagnóstico e tempo de fora de terapia. Quanto a QVRS, houve melhores resultados dos sobreviventes masculinos em relação às sobreviventes e participantes CTRL. Especificamente, GLLA e GTW para Vitalidade e GLLA para Aspectos sociais, Saúde mental e Aspectos emocionais, no último aspecto detectada diferença também para as sobreviventes GTW. Nos sobreviventes com diagnóstico tardio (acima 53 meses) o GLLA apresentou melhores resultados na Capacidade funcional. Na percepção da própria saúde, houve diferença para todos os domínios, exceto nos Aspectos sociais e emocionais, estando as diferenças circunscritas a percepções positivas (boa, muito boa e excelente) da própria saúde pelos sobreviventes e controles. Conclusão: Particularmente no período do estudo, para a amostra selecionada e os aspectos analisados pelo SF-36 pode-se inferir que, apesar de algumas diferenças encontradas, os sobreviventes não apresentaram evidências de comprometimento de QVRS. O SF-36 (via telefone) pode ser um recurso de acesso e avaliação de QVRS de sobreviventes sob acompanhamento ambulatorial
The involvement of childhood cancer is relatively rare, with relevant incidence rates of some cancers such as Acute Lymphoblastic Leukemia (ALL) and Wilms Tumor (WT). Although cancer is one of the top ten causes of death in children and adolescents and the first disease from the age of five, in recent decades the therapeutic progress has made possible a decline in mortality rates and expansion of the survival periods. In this way, the effective monitoring in the confrontation of the disease passed to seek broader analyses of later organic effects from disease and therapy, including the psychosocial conditions of survivor, as in evaluations of healthrelated quality of life (HRQoL). In order to increase knowledge and alternatives for monitoring outpatient and periodic survival condition, this study sought to compare the impact on HRQoL of adult survivor, given the difference in the choice therapy for the remission of ALL (chemotherapy) and WT (surgery) using a remote assessment of HRQoL (SF -36 via telephone call). Objectives: Analyze and compare the HRQoL of adult survivors of ALL and WT between themselves and in relation to healthy participants, followed at the Ambulatory outside ITACI - HC - USP therapy , by alternative application ( by phone calls) of the SF - 36 . Methods: 90 participants , above 18 years. Control group (CTRL): (30 subjects, physically healthy, no history of oncological diagnosis, newly joined in higher education) and experimental groups (60 survivors - Outpatient Therapy - ITACI - HCFMUSP ): ALL group ( GALL ) - 30 ALL survivors and WT group ( GWT ) 30 WT survivors. The evaluation was performed by applying SF-36, via telephone calls. After compilation of the SF -36 domains, the results were analyzed through chi - square test, independent t test and ANOVA test. Results: Participants showed no significant difference regarding age, most were single, childless and from Sao Paulo. CTRL highest level of schooling resulted from inclusion criterion but with relevant proportion of survivors at the top level. In survivors there was no significant difference in age of diagnosis and time outside therapy. As for HRQoL there have been better results of male survivors in relation to female survivors and CTRL participants. Specifically GALL and GWT for vitality domain and GALL for social aspects, mental health and emotional aspects. In the last domain, it was detected also difference female survivors GWT. In survivors with late diagnosis (above 53 months) the GALL presented better results in functional capacity. In the perception of their own health, there were differences for all domains except in social and emotional aspects, with differences confined to positive perceptions (good, very good and excellent ) of own health by survivors and controls. Conclusion: Particularly during the study period, for the selected sample and the analyzed aspects by SF -36 can be inferred that, despite some differences, survivors did not show evidence of impairment of HRQoL . The SF -36 (via telephone calls) can be a resource of access HRQoL evaluation of survivors under ambulatory followup
APA, Harvard, Vancouver, ISO, and other styles
10

Marchioro, Mariana Kliemann. "Estudo de utilização de medicamentos em uma unidade de oncologia pediátrica de um hospital universitário de Porto Alegre." reponame:Biblioteca Digital de Teses e Dissertações da UFRGS, 2013. http://hdl.handle.net/10183/101511.

Full text
Abstract:
O câncer pediátrico é raro em números absolutos, porém quando comparado às incidências em adultos vem apresentando aumento nas taxas de incidência, exigindo um preparo do sistema de saúde para acompanhamento. Este acompanhamento não pode ser igual ao do adulto, visto que crianças possuem diferenças fisiológicas nas diferentes faixas etárias pediátricas. Sendo assim, estudos de utilização de medicamentos são importantes nesta população, a fim de promover o uso racional dos mesmos, bem como, garantir seu uso seguro e uma terapêutica eficaz. O presente estudo tem por objetivo avaliar as prescrições de antineoplásicos, na unidade de oncologia pediátrica de um hospital universitário de Porto Alegre, identificando os protocolos mais utilizados, e posteriormente contextualizando-os com o preconizado no referencial teórico. Foi realizado um estudo transversal prospectivo envolvendo internações realizadas na unidade de oncologia pediátrica do Hospital de Clínicas de Porto Alegre (HCPA). Foram analisadas 274 internações, das quais 40 eram primeira internação e 234 reinternações. A maioria dos pacientes tinha idade de 0 a 10 anos, uma discreta prevalência do sexo masculino, de raça/cor branca, residentes na mesorregião metropolitana. A principal forma de financiamento das internações foi o público, e a principal causa de internação foi o tratamento, sendo o mais frequente o quimioterápico. Foram analisados os protocolos utilizados durante as internações de pacientes com diagnóstico de Leucemia Linfocítica Aguda, Retinoblastoma e Sarcoma de Ewing. Os protocolos são conjunto de regras criadas a partir de grupos cooperativos ou da indústria farmacêutica, permitindo um maior conhecimento sobre os medicamentos utilizados na pediatria. A oncologia pediátrica com sua particularidade de ser uma doença culturalmente ligada ao óbito possui maior facilidade de estudos deste porte. Porém, ainda são necessários mais estudos de utilização destes medicamentos, a fim de agregar conhecimento aos protocolos de tratamento.
Pediatric cancer is rare in absolute numbers, but when compared to the incidence in adults has shown an increase in incidence rates, requiring a prepared system health for following. Pediatrics treatment can’t be the same as that of adults, because children have different physiological differences in pediatric age groups. Studies of medication use in this population are very important in order to promote the rational use of drugs, as well as to guarantee their safe use and effective therapy. The present study aims to evaluate the anticancer prescriptions in pediatric oncology unit of a university hospital in Porto Alegre, identifying the most used protocols, and contextualizing them later with the recommendations in the theoretical framework. A prospective cross-sectional study involving hospital admissions in the pediatric oncology unit of the Hospital de Clínicas de Porto Alegre (HCPA) was performed. We analyzed 274 admissions, which 40 were first admission and 234 were readmissions. These admissions most patients were aged 0 to 10 years, white race, a slight male prevalence, residing in Metropolitan Mesoregion. The financing the hospital admissions was public, and the maining cause of hospitalization was treatment, the most frequent being the chemotherapy. We analyzed the protocols used during the admissions of patients diagnosed with Acute Lymphocytic Leukemia, Retinoblastoma and Ewing's Sarcoma. Protocols are studies that allow a greater knowledge about medicines for pediatric use. The pediatric oncology with its characteristic of being a disease has culturally linked with death ease of studies of this size. However, more studies of medication use are still needed to use these drugs in order to knowledge to the treatment protocols.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Precursor T-Cell Lymphoblastic Leukemia-Lymphoma"

1

Vecchione, Severo. Acute lymphoblastic leukemia: Etiology, pathogenesis, and treatments. Hauppauge, N.Y: Nova Science Publishers, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Pullarkat, Vinod. Contemporary management of acute lymphoblastic leukemia. New Delhi, India: Jaypee Brothers Medical Publishers (P) Ltd, 2014.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Peter, Gale Robert, and Hoelzer Dieter, eds. Acute lymphoblastic leukemia: Proceedings of a Wyeth-Ayerst-UCLA Western Workshop--Acute Lymphoblastic Leukemia, held at Tapatio Springs, Texas, November 29-December 2, 1988. New York: Wiley-Liss, 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Saha, Vaskar, and Pamela Kearns. New agents for the treatment of acute lymphoblastic leukemia. New York: Springer, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Secker-Walker, Lorna M. Chromosomes and genes in acute lymphoblastic leukemia. New York: Springer, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Childhood leukemia: A practical handbook. Heidelberg: Springer, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

H, Estey E., Faderl S. H, and Kantarjian Hagop 1952-, eds. Hematologic malignancies: Acute leukemias. Berlin: Springer, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

(Editor), Robert Peter Gale, and Dieter Hoelzer (Editor), eds. Acute Lymphoblastic Leukaemia (UCLA symposia on molecular and cellular biology). John Wiley & Sons Inc, 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Reaman, Gregory H., and Franklin O. Smith. Childhood Leukemia: A Practical Handbook. Springer, 2014.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

St-Denis, Emily Jean. The progression of precursor B cell acute lymphoblastic leukemia in murine models. 2005.

Find full text
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Precursor T-Cell Lymphoblastic Leukemia-Lymphoma"

1

Reinartz, Gabriele, Katharina Susek, and Matthias Stelljes. "Radiation Therapy in Precursor T-Lymphoblastic Lymphoma/Leukemia." In Radiation Oncology, 1–9. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-52619-5_29-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Kato, Motohiro. "B-Cell Precursor ALL." In Pediatric Acute Lymphoblastic Leukemia, 47–57. Singapore: Springer Singapore, 2019. http://dx.doi.org/10.1007/978-981-15-0548-5_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Gastier-Foster, Julie M. "Precursor B-Cell Acute Lymphoblastic Leukemia." In Molecular Pathology Library, 287–307. Boston, MA: Springer US, 2010. http://dx.doi.org/10.1007/978-1-4419-5698-9_24.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Schütt, S., K. Seeger, C. Schmidt, W. Siegert, and G. Henze. "Immunoglobulin and T-Cell Receptor Gene Rearrangements in Childhood Acute Lymphoblastic Leukemia and Non-Hodgkin’s Lymphoma." In Acute Leukemias II, 56–61. Berlin, Heidelberg: Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-74643-7_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Borowitz, M. J., A. J. Carroll, J. J. Shuster, A. T. Look, F. G. Behm, D. J. Pullen, V. J. Land, P. Steuber, and W. M. Crist. "Use of Clinical and Laboratory Features to Define Prognostic Subgroups in B-Precursor Acute Lymphoblastic Leukemia: Experience of the Pediatric Oncology Group." In Recent Advances in Cell Biology of Acute Leukemia, 257–67. Berlin, Heidelberg: Springer Berlin Heidelberg, 1993. http://dx.doi.org/10.1007/978-3-642-84895-7_23.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Meyer, C., R. A. F. MacLeod, H. Quentmeier, J. W. G. Janssen, L. Coignet, and H. G. Drexler. "Establishment of the B-Cell Precursor-Acute Lymphoblastic Leukemia Cell Line MUTZ-5 Carrying a (12;13) Translocation." In Haematology and Blood Transfusion Hämatologie und Bluttransfusion, 15–18. Berlin, Heidelberg: Springer Berlin Heidelberg, 2003. http://dx.doi.org/10.1007/978-3-642-59358-1_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Barnett, M. J., A. Z. S. Rohatiner, J. E. Kingston, K. E. Adams, E. L. Batten, R. Bassan, P. E. Thorpe, M. A. Horton, J. S. Malpas, and T. A. Lister. "In Vitro Treatment of Bone Marrow from Patients with T-Cell Acute Lymphoblastic Leukemia and Non-Hodgkin’s Lymphoma Using the Immunotoxin WT1-Ricin A." In Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, 57–58. Berlin, Heidelberg: Springer Berlin Heidelberg, 1987. http://dx.doi.org/10.1007/978-3-642-72624-8_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Trka, J., J. Zuna, M. Kalinova, O. Hrusak, R. Paukertova, T. Eckschlager, and J. Stary. "RT-PCR-Based Detection of TEL/AML1 Fusion Transcript in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia — a Czech Childhood Leukemia Working Group Experience." In Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, 229–33. Berlin, Heidelberg: Springer Berlin Heidelberg, 1998. http://dx.doi.org/10.1007/978-3-642-71960-8_29.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Sweetenham, John W. "Precursor T-Cell Lymphoblastic Lymphoma." In The Lymphomas, 456–63. Elsevier, 2006. http://dx.doi.org/10.1016/b978-0-7216-0081-9.50032-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

"Early T-Cell Precursor Acute Lymphoblastic Leukemia." In Diagnostic Pathology: Blood and Bone Marrow, 750–51. Elsevier, 2018. http://dx.doi.org/10.1016/b978-0-323-39254-9.50146-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Precursor T-Cell Lymphoblastic Leukemia-Lymphoma"

1

Sugihara, Eiji, Takatsune Shimizu, Jo Ishizawa, Seiji Okada, Masanao Miwa, and Hideyuki Saya. "Abstract 3098: Myc preferentially transforms hematopoietic stem cells into Precursor B cell lymphoblastic leukemia/lymphoma." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-3098.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Maude, Shannon L., Sibasish Dolai, Cristina Delagdo-Martin, Tiffaney Vincent, Alissa Robbins, Arthavan Selvanathan, Theresa Ryan, et al. "Abstract 997: Targeting the Jak/Stat signaling pathway is highly effective in xenograft models of early T cell precursor (ETP) acute lymphoblastic leukemia (ALL)." In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-997.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Benninghoff, Abby D., Amanda M. Hagman, Lyndsey E. Shorey, and David E. Williams. "Abstract 5441: Anticancer effects of 3,3′-diindolylmethane (DIM) in multiple T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) cell lines." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-5441.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Niedermayer, A., S. Enzenmüller, E. Tausch, S. Stilgenbauer, F. Seyfried, and LH Meyer. "Characterization of mechanisms of acquired Venetoclax-insensitivity in B-cell precursor acute lymphoblastic leukemia." In 33. Jahrestagung der Kind-Philipp-Stiftung für pädiatr. onkolog. Forschung. © Georg Thieme Verlag KG, 2020. http://dx.doi.org/10.1055/s-0040-1709773.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Bastos, Ana Clara Santos da Fonseca, Caroline Barbieri Blunck Blunck, Luciana Bueno Ferreira, Maria do Socorro Pombo-de-Oliveira, Mariana Emerenciano, and Etel R. Gimba. "Abstract 1491: Expression of osteopontin splicing isoforms in childhood B-cell precursor acute lymphoblastic leukemia." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-1491.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Summers, Ryan J., Katherine A. Minson, Eleana Vasileiadi, Xiaodong Wang, Steven V. Frye, H. Shelton Earp, Deborah DeRyckere, and Douglas K. Graham. "Abstract 1314: MERTK and BCL-2 as potential therapeutic targets in early T-precursor acute lymphoblastic leukemia." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-1314.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Summers, Ryan J., Katherine A. Minson, Eleana Vasileiadi, Xiaodong Wang, Steven V. Frye, H. Shelton Earp, Deborah DeRyckere, and Douglas K. Graham. "Abstract 1314: MERTK and BCL-2 as potential therapeutic targets in early T-precursor acute lymphoblastic leukemia." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-1314.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Summers, Ryan J., Katherine A. Minson, Xiaodong Wang, Stephen V. Frye, H. Shelton Earp, Deborah DeRyckere, and Douglas K. Graham. "Abstract A35: MERTK and BCL-2 as potential therapeutic targets in early T-precursor acute lymphoblastic leukemia." In Abstracts: AACR Special Conference: Pediatric Cancer Research: From Basic Science to the Clinic; December 3-6, 2017; Atlanta, Georgia. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.pedca17-a35.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Lenk, L., M. Carlet, A. Cousins, G. Cario, C. Halsey, I. Jeremias, E. Hobeika, H. Jumaa, A. Alsadeq, and DM Schewe. "CD79a/CD79b Promote CNS-Involvement and Leukemic Engraftment in Pediatric B-cell Precursor Acute Lymphoblastic Leukemia." In 33. Jahrestagung der Kind-Philipp-Stiftung für pädiatr. onkolog. Forschung. © Georg Thieme Verlag KG, 2020. http://dx.doi.org/10.1055/s-0040-1709765.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Lenk, L., F. Vogiatzi, M. Carlet, G. Cario, M. Schrappe, I. Jeremias, E. Hobeika, H. Jumaa, A. Alsadeq, and DM Schewe. "CD79a impacts central nervous system (CNS) infiltration of pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL)." In 31. Jahrestagung der Kind-Philipp-Stiftung für pädiatrisch onkologische Forschung. Georg Thieme Verlag KG, 2018. http://dx.doi.org/10.1055/s-0038-1645012.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Precursor T-Cell Lymphoblastic Leukemia-Lymphoma' for particular source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography